| Autor: |
Vujanovic L; University of Pittsburgh Hillman Cancer Center, Pittsburgh, PA, United States.; Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States., Chuckran C; Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States., Lin Y; University of Pittsburgh Hillman Cancer Center, Pittsburgh, PA, United States.; Department of Biostatistics, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States., Ding F; University of Pittsburgh Hillman Cancer Center, Pittsburgh, PA, United States.; Department of Biostatistics, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States., Sander CA; University of Pittsburgh Hillman Cancer Center, Pittsburgh, PA, United States.; Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States., Santos PM; University of Pittsburgh Hillman Cancer Center, Pittsburgh, PA, United States.; Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States., Lohr J; Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States., Mashadi-Hossein A; NanoString Technologies, Seattle, WA, United States., Warren S; NanoString Technologies, Seattle, WA, United States., White A; NanoString Technologies, Seattle, WA, United States., Huang A; NanoString Technologies, Seattle, WA, United States., Kirkwood JM; University of Pittsburgh Hillman Cancer Center, Pittsburgh, PA, United States.; Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States., Butterfield LH; University of Pittsburgh Hillman Cancer Center, Pittsburgh, PA, United States.; Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States.; Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States.; Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States. |
| Abstrakt: |
Natural killer (NK) cells are innate cytotoxic and immunoregulatory lymphocytes that have a central role in anti-tumor immunity and play a critical role in mediating cellular immunity in advanced cancer immunotherapies, such as dendritic cell (DC) vaccines. Our group recently tested a novel recombinant adenovirus-transduced autologous DC-based vaccine that simultaneously induces T cell responses against three melanoma-associated antigens for advanced melanoma patients. Here, we examine the impact of this vaccine as well as the subsequent systemic delivery of high-dose interferon-α2b (HDI) on the circulatory NK cell profile in melanoma patients. At baseline, patient NK cells, particularly those isolated from high-risk patients with no measurable disease, showed altered distribution of CD56 dim CD16 + and CD56 dim CD16 - NK cell subsets, as well as elevated serum levels of immune suppressive MICA, TN5E/CD73 and tactile/CD96, and perforin. Surprisingly, patient NK cells displayed a higher level of activation than those from healthy donors as measured by elevated CD69, NKp44 and CCR7 levels, and enhanced K562 killing. Elevated cytolytic ability strongly correlated with increased representation of CD56 dim CD16 + NK cells and amplified CD69 expression on CD56 dim CD16 + NK cells. While intradermal DC immunizations did not significantly impact circulatory NK cell activation and distribution profiles, subsequent HDI injections enhanced CD56 bright CD16 - NK cell numbers when compared to patients that did not receive HDI. Phenotypic analysis of tumor-infiltrating NK cells showed that CD56 dim CD16 - NK cells are the dominant subset in melanoma tumors. NanoString transcriptomic analysis of melanomas resected at baseline indicated that there was a trend of increased CD56 dim NK cell gene signature expression in patients with better clinical response. These data indicate that melanoma patient blood NK cells display elevated activation levels, that intra-dermal DC immunizations did not effectively promote systemic NK cell responses, that systemic HDI administration can modulate NK cell subset distributions and suggest that CD56 dim CD16 - NK cells are a unique non-cytolytic subset in melanoma patients that may associate with better patient outcome. |
